Mark D Booth insider trades: Orexigen Therapeutics (OREX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mark reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 26, 2015 | OREX | ↓ Sell | 50,000 | $5.68 | $284K | Direct | Mar 2, 2015 (4d) |
| Jul 26, 2013 | OREX | ↓ Sell | 64,767 | $7.55 | $489K | Direct | Jul 29, 2013 (3d) |
| Mar 11, 2013 | OREX | ↓ Sell | 27,685 | $6.67 | $185K | Direct | Mar 12, 2013 (1d) |
| Jan 15, 2013 | OREX | ↓ Sell | 22,315 | $6.67 | $149K | Direct | Jan 18, 2013 (3d) |
| Jun 28, 2012 | OREX | ↓ Sell | 103,309 | $5.66 | $585K | Direct | Jun 29, 2012 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mark D Booth's insider trades
Mark D Booth is Chief Commercial Officer at Orexigen Therapeutics (OREX). Since Jun 28, 2012, Mark has reported no open-market purchases and 5 sales worth $1.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (12 filings), option exercises (5 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OREX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.